Cargando…

HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium

PURPOSE: Hypoxia is a common phenomenon encountered in solid cancers, leading to chemotherapy resistance and therefore to aggressiveness of the disease. The homeostatic response to hypoxia is mediated by hypoxiainducible factor-1 (HIF-1). The aim of this study was to investigate the impact of HIF1α...

Descripción completa

Detalles Bibliográficos
Autores principales:	Braicu, Elena Ioana, Luketina, Hrvoje, Richter, Rolf, Cacsire Castillo-Tong, Dan, Lambrechts, Sandrina, Mahner, Sven, Concin, Nicole, Mentze, Monika, Zeillinger, Robert, Vergote, Ignace, Sehouli, Jalid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166345/ https://www.ncbi.nlm.nih.gov/pubmed/25246800 http://dx.doi.org/10.2147/OTT.S65373

Ejemplares similares

Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium
por: Trillsch, Fabian, et al.
Publicado: (2013)

Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium
por: Aust, Stefanie, et al.
Publicado: (2014)

Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium
por: Obermayr, Eva, et al.
Publicado: (2017)

The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium
por: Obermayr, Eva, et al.
Publicado: (2021)

Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer—A Study of the OVCAD Consortium
por: Obermayr, Eva, et al.
Publicado: (2021)

Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium
por: Bachmayr-Heyda, Anna, et al.
Publicado: (2013)

A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer - a study of the OVCAD consortium
por: Pils, Dietmar, et al.
Publicado: (2013)

Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium
por: Aust, Stefanie, et al.
Publicado: (2012)

Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer
por: Mungenast, Felicitas, et al.
Publicado: (2017)

AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer
por: Svoboda, Martin, et al.
Publicado: (2016)

Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) – a study of the TOC Consortium
por: Braicu, Elena Ioana, et al.
Publicado: (2014)

Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study
por: Watrowski, Rafał, et al.
Publicado: (2022)

Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer
por: Meshcheryakova, Anastasia, et al.
Publicado: (2019)

Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer
por: Svoboda, Martin, et al.
Publicado: (2018)

Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2020)

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium
por: Ray-Coquard, Isabelle, et al.
Publicado: (2019)

Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
por: Glajzer, Jacek, et al.
Publicado: (2022)

Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test)
por: Kischkel, Frank Christian, et al.
Publicado: (2017)

Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
por: Ruscito, Ilary, et al.
Publicado: (2018)

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer()
por: Stanske, Mandy, et al.
Publicado: (2018)

Fertility-Sparing Surgery in Early Epithelial Ovarian Cancer: A Viable Option?
por: Fotopoulou, Christina, et al.
Publicado: (2012)

Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group
por: Trillsch, Fabian, et al.
Publicado: (2021)

Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis
por: Baum, Joanna, et al.
Publicado: (2023)

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer
por: Hofstetter, G, et al.
Publicado: (2011)

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer
por: Woopen, Hannah, et al.
Publicado: (2014)

Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab
por: Seeber, Andreas, et al.
Publicado: (2015)

Chondroitin Sulfate Disaccharides, a Serum Marker for Primary Serous Epithelial Ovarian Cancer
por: Biskup, Karina, et al.
Publicado: (2021)

Can a morphological description of the peritoneal carcinomatosis in advanced ovarian cancer add prognostic information? Analysis of 1686 patients of the tumor bank ovarian cancer
por: Nasser, Sara, et al.
Publicado: (2022)

Sialic Acid Linkage Analysis Refines the Diagnosis of Ovarian Cancer
por: Dědová, Tereza, et al.
Publicado: (2019)

Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study
por: Maritschnegg, Elisabeth, et al.
Publicado: (2015)

Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis
por: Cherif, Soumia, et al.
Publicado: (2021)

Predictive and Prognostic Value of sPRR in Patients with Primary Epithelial Ovarian Cancer
por: Kreienbring, Katrin, et al.
Publicado: (2016)

3D ultrasound as a surgical quality control of conization in patients with severe dysplasia: a prospective study
por: Dückelmann, Anna M., et al.
Publicado: (2020)

The Serum Glycome to Discriminate between Early-Stage Epithelial Ovarian Cancer and Benign Ovarian Diseases
por: Biskup, Karina, et al.
Publicado: (2014)

Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ)
por: Chekerov, Radoslav, et al.
Publicado: (2023)

In Situ N-Glycosylation Signatures of Epithelial Ovarian Cancer Tissue as Defined by MALDI Mass Spectrometry Imaging
por: Grzeski, Marta, et al.
Publicado: (2022)

Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism
por: Niemi, Riikka Johanna, et al.
Publicado: (2018)

A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer
por: Salminen, Liina, et al.
Publicado: (2021)

Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer
por: Lambrechts, Sandrina, et al.
Publicado: (2015)

Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers
por: Gschwantler-Kaulich, Daphne, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ukd1kbt9v0u4vlo9jfekf7mck7